Current Edition

CVR

Pacira boosts non-opioid pain portfolio via $450M Flexion buy, with more CVR payments to come

Delivering postsurgical analgesic Exparel to blockbuster land is no longer enough for Pacira BioSciences’ appetite. The company is now reaching for its mergers and acquisitions …

Continue Reading →